Placental alkaline phosphatase (PLAP) is present on the syncytiotrophoblast after the twelfth week of pregnancy and can be found in trace amounts in normal cervix, thymus, lung (Goldstein et al., 1982; Nouwen et al., 1986) , ovary and oviduct (Nouwen et al., 1987) . The closely related germ cell alkaline phosphatase (GCAP, formerly PLAP-like AP) occurs in very small amounts in normal testis (Chang et al., 1980) . Both isoenzymes display a high degree of polymorphism, and phenotypes can be distinguished electrophoretically (Robson & Harris, 1965) or by their reactivities with monoclonal antibodies (Millan & Stigbrand, 1983; Hendrix et al., 1990) . PLAP or GCAP are expressed in large amounts on the plasma membrane of ovarian tumours and seminomas, from where they can be released into patient serum in detectable amounts. Elevated levels of PLAP or GCAP have indeed been observed in the sera of ovarian cancer and seminoma patients (De Broe & Pollet, 1988 ; Koshida & Wahren, 1990) .
The aim of this study was to further examine the usefulness of PLAP as a target molecule for radioimmunodetection of tumours using two of our recent anti-PLAP monoclonal antibodies (7E8 and 17E3) in experimental immunolocalisation studies. Since PLAP expression of human tumour cells transplanted in nude mice is known to be subjected to modulation (Jeppsson et al., 1984) , we used a new recombinant cell line (MO4 1-4) in which PLAP was constitutively expressed under the control of the SV40 large T promotor. Moreover, it has been described that in vitro characteristics of antibodies do not always correlate with their in vivo tumour localisation capacities (Pimm et al., 1987; Sakahara et al., 1988) . We therefore also sought to determine if both in vitro specificity and affinity of the two anti-PLAP antibodies are reflected in the binding properties of the antibodies to tumours in vivo. We included an F(ab')2 fragment since it has been suggested that the use of antibody fragments may improve the localisation of tumours due to faster blood clearance rates and improved tumour penetration (Wahl et al., 1983; Buchegger et al., 1983; Buchegger et al., 1986; Andrew et al., 1986) .
Materials and methods
Tumour cell lines M04 1-4 cells originated from virally transformed M04 mouse fibrosarcoma cells (Billiau et al., 1973) . Via electroporation using a Baekon 2000 advanced gene transfer system (Baekon Inc., Saratoga, CA), an expression vector of about 11.6 kbases was transfected into these M04 cells. In this vector, both the cDNA encoding human PLAP type 2 (kindly provided by Dr J. Millan, La Jolla Cancer Research Foundation, La Jolla, CA) (Millan, 1986) , and the neo-gene were driven by the SV40 early promotor; the dihydrofolate reductase gene, enabling eventual amplification, was controlled by the adeno 2 major late promoter. SV40 polyadenylation and termination signals were also provided. Selection of recombinant M04 1-4 cells was done in the presence of geneticin (1 mg ml 1). Cells were grown in monolayer culture at 37'C in a humidified atmosphere with 5% CO2 and passaged every 3-4 days in RPMI 1640 medium (Gibco, Paisley, Scotland, UK), supplemented with 10% FCS. Prior to injection into nude mice, the cells were cultured in the presence of geneticin for at least eight passages and harvested at early confluency. When cultured in the absence of geneticin, PLAP expression remained stable for at least 20 passages.
5583-S cells were kindly provided by Dr M. Mareel (Laboratory for Experimental Cancerology, University Hospital, Ghent, Belgium). These cells were established from a mucinous colonic adenocarcinoma with a high production of CEA (Verstijnen et al., 1987) . The 5583-S cells grow as multicellular floating spheroids at 37°C, 5% C02, and were passaged every 3-4 days in DMEM medium (Gibco) containing 15% FCS.
Ortho Pharmaceutical Corporation (New Brunswick, NJ). Both 7F and OKT3 were unreactive with PLAP. Antibody fragmentation F(ab')2 fragments of antibodies 7E8 and OKT3 were obtained by digestion with insolubilised pepsin as recommended by the manufacturer (Pierce, Rockford, IL). Separation of Fc and F(ab')2 fragments was performed by chromatography on Prosep A and by HPLC anion exchange on TSK PW 5 DEAE (Pharmacia, Uppsala, Sweden), monitored by SDS-PAGE (Laemmli, 1970) .
Radiolabelling
Intact antibodies and fragments were radiolabelled with 1251I (Amersham, Brussels, Belgium) using the chloramine T procedure (Greenwood et al., 1963) at a molar ratio of chloramine T/IgG and chloramine T/F(ab')2 of 205 and 148, respectively. Chromatograms obtained upon gel filtration on a Sephadex S-300 column (1 x 30 cm), equilibrated in PBS containing 2% BSA, indicated that no antibody aggregation had occurred during labelling. The labelling efficiency ranged from 57.8% to 66.2% for intact antibodies, and from 11.8% to 18.3% for F(ab')2 fragments. The corresponding specific activities varied from 28.9 to 33.1 mCi mg-' for intact antibodies and from 5.2 to 9.2 mCi mg-' for the fragments.
Affinity and immunoreactivity of antibodies and antibody fragments before and after radiolabelling
Competition sandwich ELISA Before labelling, the affinity of the anti-PLAP antibody 7E8 and its F(ab')2 fragment were compared in a competition sandwich ELISA in which increasing concentrations (0-167 nM) of intact 7E8 or 7E8 F(ab')2 were allowed to compete with intact, biotin-labelled 7E8 (16.7 nM) for binding to PLAP, immobilised in microtitre plates.
Flow cytometry Membrane binding of the intact anti-PLAP antibodies 7E8 and 17E3, the F(ab')2 fragments of 7E8, the anti-CEA antibody, and the OKT3 antibody and its fragment with M04 1-4 cells, 5583-S cells, or human peripheral blood mononuclear cells (PBMCs) was determined by flow cytometry. PBMCs were prepared from heparinised blood from a normal donor by Fycoll-Hypaque (Pharmacia) centrifugation. M04 1-4 cells, 5583-S cells, and PBMCs were counted and adjusted to 107 viable cells per ml in HBSS (Gibco), containing 20% denatured normal horse serum and 0.01% NaN3 and incubated at OC for 1 h upon addition of antibodies (4 gsg ml-'). Thereafter, cells were washed and incubated with a fluorescein-conjugated rabbit antimouse Ig F(ab')2 fragment (Dakopatts, Glostrup, Denmark) . After 1 h at 0°C, cells were washed and analysed in a FACS-TARPPI" cell sorter (Becton Dickinson Immunocytometry Systems, Mountain View, CA). Results are expressed as the mean linear fluorescence intensity from 10,000 cells analysed.
Enzyme Antigen Immunoassay (EAIA) Antigen affinity of 7E8 IgG, 7E8 F(ab')2, or 17E3 IgG was compared before and after radiolabelling in an in vitro EAIA as described (Hendrix et al., 1990) . Briefly, microtitre plates precoated with rabbit anti-mouse polyclonal antiserum were saturated with unlabelled and '25I-labelled intact antibodies or their F(ab')2 fragments. After washing, 2ng (1001tl) of PLAP was incubated overnight at 4°C. The alkaline phosphatase activity bound to the antibodies (B) and the initial, total activity (T) were then measured in an EAR Multi-well reader (SLT Labinstruments, Gr6dig, Austria), and the percentage binding (B/T x 100) was calculated.
Live cell-binding assay The immunoreactivity of antibody preparations before and after labelling was also compared in an in vitro live cell-binding assay. M04 1-4 and 5583-S cells were suspended at 5 x 106 cells ml-' in PBS in the presence of antibody (20 ng ml -), corresponding to a 10-fold molar excess of antigen to antibody. Selectivity of tumour uptake Selective tumour uptake of the different antibodies was determined by comparing the tumour/non-tumour ratios found for these antibodies, i.e. the ratios of activity in tumour to activity in normal, nontumour tissues, according to the formula: SI = tumour/nontumour tissue = % injected dose per g tumour/% injected dose per g non-tumour tissue. This ratio was calculated for nine normal tissues, including kidneys, intestines, liver, spleen, heart, lung, skeletal muscle, bone and fat tissue. Due to skewness, means were expressed as geometric means and the Mann-Whitney U test was used to compare SI's for the M04 1-4 tumour and the 5583-S tumour. The tumour/kidney ratio was excluded when mean SI were calculated for the F(ab')2 fragments.
Specificity of tumour localisation The localisation index (LI)
was defined as the ratio of specific to non-specific antibody uptake in tumours and other tissues, divided by the same ratio in the blood (Moshakis et al., 1981) : LI = % dose per g tumour/% dose per g blood (for specific antibody) divided by % dose per g tumour/% dose per g blood (for non-specific antibody).
Pharmacokinetic analysis
At each time point, tissue concentrations of radioactive antibody (% of injected dose per g tissue) were averaged for three mice. Data of mean concentration vs time were analysed by least square nonlinear regression using the BMDP Statistical Software (Dixon, 1988) . When calculated this way, the a and P elimination rate constants had standard deviations below 10%. The corresponding tissue half-life values were calculated as t/2 = 0.693/,. The area under the concen-tration x time curve (AUC) was determined using the trapezoidal rule.
Imaging studies Scintigraphic imaging was performed at various time points after antibody administration. Mice were anesthetised with pentobarbital (Nembutal, Abbott, Ottignies, Belgium; 40 mg kg-') and imaging was performed using a mobile gamma camera (Technicare, Sigma 4205, Ohio Nuclear Inc., OH) equipped with a high resolution, parallel hole collimator. Analog and digital images were made ventrally, with the animals positioned directly on the collimator. Images were acquired for approximately 70,000 counts, resulting in imaging times of 10 to 30 min. Digital images were normalised using a Sophy P computer (Sopha Medical, Buc, France). Following final imaging, the mice were dissected and the radiolabelled antibody distribution was calculated as described above.
Histochemical and immunohistochemical studies M04 1-4 cells and 5583-S cells were stained histologically and immunohistologically for the presence of PLAP or CEA. These cells were analysed before injection in mice, after passage in these mice, or after passage in cell culture (in the absence of geneticin) for as long as the cells were growing in the developing tumours. Tumour sections taken at the start and at the end of the experiment were stained as described (Nouwen et al., 1987 ) using a polyclonal anti-PLAP antiserum (Analis, Namur, Belgium) and anti-CEA antiserum (Dakopatts).
Histological staining for PLAP activity was done according to the method of Gossrau (Gossrau, 1978) . To eliminate the activity of endogenous mouse tissue non-specific AP in stromal capillaries, the sections were pre-treated by heating (5 min, 65°C).
Results
Characterisation of PLAP expressed by recombinant M04 1-4 cells Before using the PLAP-transfected M04 1-4 tumour cells as antibody targets in vivo, the PLAP antigen produced by these cells was fully characterised with respect to its heat stability, enzyme kinetics, inhibitor sensitivity, reactivity with monoclonal antibodies, and electrophoretic mobility in starch gel or paragon electrophoresis. Essentially, no differences were detected between the PLAP extracted from M04 1-4 cells and from placenta, type 2. Immunohistochemical and electron microscopic observations revealed that PLAP was localised on the external surface of the plasma membrane of all M04 1-4 cells, although the PLAP expression varied quantitatively between cells.
Tumour growth and antigen expression in growing tumours One hundred thousand M04 1-4 cells and 107 5583-S cells were subcutaneously injected in the right and left thighs of nude mice, respectively. The tumours appeared within 8 days after injection with an incidence of 100%. There was no formation of metastases or ascites, not even after 5 weeks. The amounts of cells injected were adjusted so as to obtain tumours of comparable size in both thighs during the experiments. The average weight of M04 1-4 and 5583-S tumours at the onset of antibody administration was 0.41 ± 0.17 g and 0.49 ± 0.12 g, respectively (n = 15). Microscopically, necrosis was not seen in tumours of this size.
PLAP activity measurements in M04 1-4 tumour extracts, as well as histochemical PLAP stainings in tumour tissues (Figure la,b) , showed an abundant PLAP expression on the plasma membranes of the M04 1-4 tumour cells throughout the duration of the study, at a fairly constant level of 3.84 ± Affinity and immunoreactivity of antibodies and their F(ab')2 fragments The most intense immunohistochemical staining levels on non-fixed M04 1-4 cells were obtained using the anti-PLAP monoclonal antibodies 7E8 and 17E3 (affinity constants of 9 x 108 M and 0.9 x I01 M-I, respectively). A sufficient amount of F(ab')2 fragments could only be obtained for 7E8 and for the negative control antibody OKT3. The affinity of antibody 7E8 and its F(ab')2 fragment were compared in a competition sandwich ELISA: intact 7E8 and 7E8 F(ab')2 competed equally well with biotinylated intact 7E8 for binding to PLAP.
Immunoreactivity analysis of 7E8 and 7E8 F(ab')2, 7F, OKT3, and OKT3 F(ab')2 with M04 1-4, 5583-S cells, or human lymphocytes by indirect immunofluorescence with fluorescein-conjugated rabbit anti-mouse Ig F(ab')2 fragments indicated that each antibody reacted specifically with cells expressing the corresponding antigen and confirmed that 7E8 reacts better with PLAP than 17E3. Reactivities of F(ab')2 fragments corresponded to those of the intact antibodies.
Affinity and immunoreactivity of radiolabelled antibodies and F(ab')2 fragments Molar ratios of incorporated 1251I into the antibodies were maximally 2.9 for intact antibodies and 0.6 for F(ab')2 fragments. Analysis in EAIA indicated no important losses in affinity after radiolabelling of intact 7E8, 17E3, and 7E8 F(ab')2 (data not shown). Unlabelled as well as radiolabelled 7F IgG and OKT3 F(ab')2 fragments were unreactive with the PLAP antigen in EAIA. In addition, we compared the capacity of unlabelled and labelled antibody preparations to bind to both tumour target cells presenting an excess of antigen in a live cell-binding assay. Total and unbound antibody concentrations were determined by standard ELISA procedures. Also, the ratio c.p.m. cell-bound/c.p.m. added was calculated for the radiolabelled antibodies. The percentage binding obtained either way was identical, i.e. the introduction of 125I-label in the antibody preparations did not cause any important loss in immunoreactivity. In addition, both assays confirmed the higher PLAP binding by 7E8 than by 17E3.
Biodistribution and pharmacokinetics of radiolabelled intact antibodies 7E8, 17E3, and 7F Anti-PLAP antibodies 7E8 and 17E3, or the anti-CEA antibody 7F were injected i.p. as intact antibodies in nude mice, bearing PLAP-expressing M04 1-4 tumours and CEAexpressing 5583-S xenografts at contralateral thighs. This way, we could evaluate the tumour-localising capacities of all antibodies with built-in reciprocal controls at the level of tumour type and antibody specificity. Blood, tumours, and tissues from three animals per group were sampled for weighing and c.p.m. counting at 6 h, and on day 1, 3, 6, 8, 10 and 13 after injection.
The mean accumulation indices (Al, % of injected dose per g tissue) for blood, M04 1-4 tumours, 5583-S tumours, and relevant non-tumour tissues are depicted in a semi-log plot of concentration vs time (Figure 2a,b,c) . Elimination curves of the iodinated intact antibodies from the blood and from non-tumour tissues were similar for all three antibodies. Antibody levels in blood rose to peak levels between 6 h and 24 h at 9.6 to 14.3% of injected dose per g blood. Peak tissue concentrations in antigen-positive tumours occurred on day 1 for 7E8 and 17E3 (3.3 ± 0.5 %/g and 5.0 ± 0.6 %/g, respectively) and on day 6 for 7F (4.0 ± 0.6%/g). In control tumours and normal tissues, this occurred on day 1 for all the antibodies (between 2 and 3 %/g). For all three antibodies, antigen-negative control tumour curves were slightly above the non-tumour tissue curves. For antibody 17E3 a significantly higher uptake was observed in the M04 1-4 tumour as compared to the control tumour on day 1 (P < 0.005) and 3 (P< 0.05). For antibodies 7E8 and 17E3, blood always contained a higher concentration than normal or tumour tissue. In the case of 7F, tumour retention remained high, and after day 10, the 5583-S tumour curve had even crossed the blood curve. From day 6 onwards antibody uptake in the antigen-presenting tumour was significantly higher as compared with the control tumour (P<0.05 until P<0.001).
Pharmacokinetic parameters derived by regression analysis from the concentration (% of injected dose/g) x time data are summarised in Table I . For 7E8, no difference in t1/2 was seen between antigen-expressing tumour, control tumour, or non-tumour tissue. The AUC value for both tumour types was identical and slightly higher than for normal tissues. However, when 17E3 was injected, the AUC for the PLAP containing M04 1-4 tumour was higher as compared with the value for the control tumour. For 7F, the t1/2 and AUC for the CEA-positive tumour were almost twice the value found for the control tumour.
The selectivity of tumour uptake (SI) was calculated as tumour vs non-tumour tissue ratios for the antigen-expressing tumour as well as for the control tumour (data not shown). When 7E8 was injected, mean SI's ranged between 1.1 and 3.0 for both tumour types and for nine different normal tissues. Three days after injection of 17E3 a higher mean SI was found for the M04 1-4 tumour (SI = 4.8; range = 2.3-11.2), than for the control tumour (SI = 2.6; range 1.2-6.5) (P= 0.07). After administration of 7F, the mean SI for the CEA-positive tumour increased progressively to 12.9 (56.2-45.5) on day 13 after injection, while the ratio for the control tumour remained 1.7 (0.7-5.9) (P<0.05 from day 6 onwards and P<0.001 on day 13).
In Table II body injection. No specific localisation of the M04 1-4 tumour was seen with 7E8 or 17E3. The specificity of 5583-S tumour localisation by 7F was documented by increasing indices, up to a mean value of 4.52 at day 13 after antibody injection.
Biodistribution and pharmacokinetics of radiolabelled 7E8 and OKT F(ab')2 fragments We evaluated whether the use of F(ab')2 fragments would improve the localisation of the PLAP-presenting M04 1-4 tumour. Since pepsin digestion of intact 17E3 turned out to be unsuccessful, we restricted our analysis to the evaluation of the specific tumour localisation competence of 7E8 F(ab')2 fragments. OKT3 F(ab')2 was used as non-specific control fragments and the 5583-S tumour as an antigen-negative control tumour. Blood, tumour, and tissue sampling was performed at 6, 16, 26, 36, 46 and 76 h after radiolabelled antibody injection. Additional blood sampling was done at 0.5, 1, 2 and 4h.
F(ab')2 fragments of 7E8 and OKT3 were eliminated from the blood and non-tumour tissues at a similar rate: much faster clearance than was seen for intact antibodies (Figure   2d ,e). Antibody fragment levels in blood peaked at 2 h at 7.5 ± 0.6% of injected dose per g blood, but already decreased below 2%/g at the 16th hour. Peak concentrations in M04 1-4 tumour occurred at 6 h for 7E8 F(ab')2 (6.70 + 0.01 %/g) and remained above 1 %/g until 46 h after injection. Peak concentrations in normal tissues were 2.0 ± 0.2%/g at 6 h and already decreased below 0.4%/g at 16 h. For the non-specific OKT3 F(ab')2 fragments, maximum concentra- [19] [21] [5] [7] [22] [99] tions in tumour and non-tumour tissues were below 2% of injected dose/g at 6 h and decreased rapidly below 0.5%/g. Elimination profiles of antibody fragments from the kidneys were depicted separately since, in contrast to what was found with intact antibodies, they contained significantly higher radioactivity concentrations. For 7E8 F(ab')2 fragments, the M04 1-4 tumour curve was situated above the control tumour and normal tissue curves from the first time point onwards (P<0.05 until P<0.001); it crossed the blood curve already at 6 h and the kidney curve was crossed before 16 h. For the non-specific OKT3 F(ab')2 fragments, no difference was seen between profiles from PLAP-expressing tumour, control tumour, and normal tissue; the blood and kidney curves remained the highest throughout the experiment.
The pharmacokinetic parameters t1/2 and AUC, calculated for the 7E8 F(ab')2 fragments (Table I) , were much higher for the M04 1-4 tumour, than for blood, control tumour, and non-tumour tissues. By contrast, all t1/2 and AUC values were comparable for the clearance of OKT3 F(ab')2. For both antibody fragments, the kidney AUC was elevated.
While no selective tumour uptake was seen for intact 7E8 antibody, its F(ab')2 fragments showed significantly elevated tumour/non-tumour tissue ratios for the antigen-presenting M04 1-4 tumour (Figure 3 ). Higest selective tumour uptake was found at 46 h after injection with a geometric mean SI for eight normal tissues of 34.5 (14.7-118.3). The ratio for the PLAP-negative 5583-S tumour remained between 1.3 and 2.9 (P < 0.001 from 16 h after injection onwards). In Figure  3 selectivity indices are furthermore given in detail for kidneys and eight other normal tissues at different time points after injection of 7E8 F(ab')2. In the control experiment with OKT3 F(ab')2 fragments, all tumour/non-tumour tissue ratios were about one (results not shown).
The M04 1-4 tumour localisation by 7E8 F(ab')2 can be considered specific, since tumour to blood ratios were always lower for the control OKT3 F(ab')2 fragments than for the specific 7E8 F(ab')2 fragments. LI values, calculated for 7E8 F(ab')2, using OKT3 F(ab')2 as the non-specific fragment, are shown in Table II .
Imaging results
Scintigraphic images were obtained on days 6, 8, 10, and 13 after i.p. injection of radiolabelled intact 7F, 7E8, or 17E3 in nude mice, bearing a M04 1-4 tumour and a 5583-S tumour in the right and left thighs, respectively. Imaging of the M04 1-4 tumour by intact 17E3 at day 6 is shown in Figure 4a . Antibody 7F produced a clear image of the CEA-expressing tumour on days 10 and 13 (Figure 4b ). The negative controls (antigen-negative tumour; non-specific antibodies) confirmed the specificity of the tumour imaging.
Upon injection of 1251I-labelled F(ab')2 fragments, scintigraphic images were obtained from 16 to 39 h after injection. These images showed a reduction in blood pool radioactivity in normal tissues and in the control tumour as compared with intact antibodies. The 7E8 F(ab')2 fragments were pre- Time after injection of 7E8 F(ab'2 (hours) Figure 3 Selective tumour uptake (SI) of 7E8 F(ab')2 fragments at different time points after injection of this antibody fragment (note the logarithmic scale on, the Y-axis). Results are expressed as tumour/non-tumour tissue ratios, calculated for both the target tumour and the internal control tumour. The SI were separated determined for intestines (i), liver (ii), spleen (s), heart (h), lung (lu), muscle (m), bone (b), and fat tissue (f). Also the SI found for kidneys (k) is indicated, although this was not included in the calculation of the geometric mean. 0, M04 1-4 tumour; 0, 5583-S tumour; bar, geometric mean; *, P<0.05; ***, P<0.001. ferentially retained in the PLAP-expressing M04 1-4 tumour (Figure 4c) , and another high activity spot was possibly the stomach (Andrew et al., 1986) . The OKT3 F(ab')2 fragments did not show any preferential uptake (Figure 4d ). At the end of these scannings, the mice were dissected and tissue radioactivity was counted. The biodistribution results in these mice were very similar to those from the biodistribution experiments described above (data not shown): at 39 h after injection, the mean tumour (MO4 1-4)/non-tumour tissue ratios for the mouse injected with 7E8 F(ab')2 or with OKT3 F(ab')2 were 15.6 and 1.4, respectively. Similar ratios for the control (5583-S) tumour were 1.7 and 1.3, respectively.
Discussion
In this study we describe a novel in vivo model for immunotargeting of PLAP-presenting tumours, grown in the thighs of nude mice bearing size-matched control tumours grown in the opposite thigh. M04 1-4 cells were derived from the virally transformed murine M04 fibroblast cells upon transfection with a cDNA of human PLAP (type 2). The tumour incidence (100%), latency times, and tumour growth curves found for transfected M04 1-4 cells were similar to results obtained for nontransfected M04 cells which have been documented previously (Mareel et al., 1975; Meyvisch & Mareel, 1982) . Our detailed characterisation of the PLAP synthesised by the M04 1-4 cells confirmed that all enzymatic and immunologic properties were conserved, and that it was localised on the outer surface of the plasma membrane of these M04 1-4 cells, making it an ideal target for tumour localisation and imaging. Most significantly, PLAP synthesis by M04 1-4 cells was found to be stable during passage in nude mice. This made the transfected M04 1-4 cells a preferred model over previously described PLAP-models based on Hela cells, which were subject to a 50-60% loss of PLAP expression during passage in nude mice (Jeppsson et al., 1984) .
Theoretically, if two idiotypic antibodies with different affinity constants are targeted to the same tumour-associated antigen, the one with the highest affinity should lead to higher selective tumour uptake and better scintigraphic images. However, other factors than in vitro binding activities can also influence tumour lcoalisation in vivo. For instance, heterogeneity of the antigen expression and the context of antigen-presentation on the tumour cells, as well as vascular permeability in the tumour may be of importance in antibody-mediated tumour localisation. Moreover, it has been shown that normal immunoglobulins, labelled with radioisotopes and injected in experimental animals, accumulate to a larger extent in tumour xenografts than in normal tissues (Bale et al., 1980) . This has been explained by the disorganised cellular growth in tumours, causing impaired lymphatic drainage of non-specific IgG leaked into the larger interstitial tumour space. Furthermore, the antibody subclass (Eccles et al., 1989) , type of radionuclide (Sakahara et al., 1988) , as well as the labelling method and labelling efficiency (Matzku et al., 1985; Pimm & Baldwin, 1987b) have all been shown to alter biodistribution and tumour targeting capabilities of monoclonal antibodies.
Appropriate experimental conditions to exclude non-specific trapping of antibodies in tumour tissue or differences in organ uptake due to subclass specificity were developed in a two-tumour/two-antibody system using size-matched PLAPpositive vs internal control tumours, and PLAP-specific vs non-specific monoclonal antibodies of the same IgGI subclass (except for the OKT3 fragments). In this system, we compared the in vivo tumour localisation ability of two radioiodinated intact monoclonal antibodies, 7E8 (Pimm & Baldwin, 1985; Pimm & Baldwin, 1987b (Hedin et al., 1982; Buchegger et al., 1983; Pimm et al., 1989) .
In spite of apparently favourable antigen and antibody characteristics of the PLAP/anti-PLAP system, selectivity and specificity of tumour localisation using intact antibodies was poor. It has been reported that affinity and specificity of binding in vitro do not necessarily predict selectivity and specificity of uptake in vivo (Mann et al., 1984; Sakahara et al., 1988 (Buchegger et al., 1983; Wahl et al., 1983; Herlyn et al., 1983; Durbin et al., 1988) . Fab fragments were omitted from this study since they are reported to be inferior to F(ab')2 fragments and unsuitable for use in patients due to their low absolute tumour uptake, very high clearance rates, and in vivo instability (Wahl et al., 1983; Durbin et al., 1988) .
The production of F(ab')2 fragments, however, may be hampered because of the unpredictability of pepsin digestion (Mather et al., 1987; Lamoyi & Nisonoff, 1983; Durbin et al., 1988) . In our hands, pepsin digestion of the antibodies proved satisfactory for 7E8 and OKT3 only. The latter antibody is of the IgG2a subclass, but blood clearance rates for 7E8 F(ab')2 and OKT3 F(ab')2 were similar and no preferential uptake in any tissue was seen for the OKT3 F(ab')2 fragment, making it suitable as a non-specific control for 7E8 F(ab')2. Although labelled 7E8 and its F(ab')2 fragment had comparable affinities for purified PLAP and for PLAP in vitro on the cell surface, the F(ab')2 fragments had quite different biodistribution and tumour localisation properties as compared with results for intact antibody. In accordance with earlier reports (Buchsbaum et al., 1988; Durbin et al., 1988) , we found that F(ab')2 fragments were cleared more rapidly from blood than intact antibody, with a catabolic phase half-life of 4 to 5 h, as compared with 62 to 107 h for intact antibodies. Elimination rates of 7E8 F(ab')2 fragments from control tumour and non-tumour tissue were much higher than from the PLAP-positive tumour. The uptake of 7E8 F(ab')2 fragments was only elevated in the kidney, which is known as a major site of fragment catabolism in mice (Covell et al., 1986) . It has been reported that F(ab')2 fragments have reduced absolute tumour uptake compared with intact IgG (Buchegger et al., 1983; Blumenthal et al., 1989; Sharkey et al., 1990) . However, we found that peak levels of F(ab')2 fragments in antigen-expressing tumour (at about 7.5% of injected dose/g, 2 h after injection) were even higher than those found for intact antibodies. Thereafter, the level of fragments declined faster than that of intact antibody. It has been thought that intra-tumour catabolism of fragments pro-ceeds faster than catabolism of intact antibodies (Pimm & Baldwin, 1987a; Endo et al., 1987; Pimm et al., 1989) .
When selective tumour localisation was expressed as tumour to non-tumour tissue ratio, 7E8 F(ab')2 fragments scored about 12 times better than intact 7E8 and seven times better than intact 17E3 (mean geometric SI was 34.5 at 46 h). In addition, tumour localisation by 7E8 F(ab')2 fragments was highly specific with a localisation index of 29.0 at 46 h. As expected, excellent imaging of M04 1-4 tumours with 7E8 F(ab')2 fragments was obtained upon gamma camera recording. These results complement the earlier findings obtained for localisation of HeLa cell tumours via the PLAP/anti-PLAP system with polyclonal or monoclonal antibodies (Jeppsson et al., 1984) and antibody fragments (Durbin et al., 1988; Stigbrand et al., 1989) , although the latter authors report a higher efficiency for intact antibodies than for F(ab')2 fragments.
In conclusion, we can state that (1) recombinant M04 1-4 tumours grown in the thighs of nude mice are a useful in vivo model for tumour immuno-targeting due to their stable expression of PLAP on the plasma membrane; (2) it is possible to discriminate PLAP-expressing tumours in nude mice, using a 125I-labelled monoclonal antibody with a rather low affinity for PLAP (17E3); and (3) excellent selective and specific immunolocalisation and high imaging efficiency of the same tumours is achieved upon injection of F(ab')2 fragments of the high affinity 7E8 antibody which, when injected as intact antibody, did not result in meaningful tumour localisation.
